It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
originally posted by: Stevenmonet
I found an article with a great chart in it. This chart is the only one that matters regarding this argument in my humble opinion.
It gives us a 40,000 ft. view of the hydroxy issue.
www.zerohedge.com...
If anyone can look at the chart in the above zerohedge article and still have any doubt as to the efficacy of prescribing hydroxy as part of the treatment regime for covid 19 they are being willfully ignorant or worse.
You decide!
originally posted by: UKTruth
originally posted by: Stevenmonet
I found an article with a great chart in it. This chart is the only one that matters regarding this argument in my humble opinion.
It gives us a 40,000 ft. view of the hydroxy issue.
www.zerohedge.com...
If anyone can look at the chart in the above zerohedge article and still have any doubt as to the efficacy of prescribing hydroxy as part of the treatment regime for covid 19 they are being willfully ignorant or worse.
You decide!
It's quite possible that those spreading the propaganda that it does not work - all because they hate Trump - have contributed to the deaths of many thousands of people.
originally posted by: Southern Guardian
a reply to: Fallingdown
There is a recent peer reviewed paper that disputes your position.
Where's the source?
originally posted by: Southern Guardian
There have been a number of promising treatments against COVID19 so it's any wonder why people are still hung up on Hydroxychloroquine?
Stating the fact that France and South Korea had very successful outcomes with HCQ
Korean health authorities also advised the dropping of hydroxychloroquine after a study found the decades-old malaria drug
The results from two new drug trials have failed to find evidence that hydroxychloroquine works to treat Covid-19. And a new peer review by one of Europe’s top doctors has found the study conducted by French professor Raoult
A controversial Lancet study in late May reported that they had found no proof that hydroxychloroquine could efficiently treat Covid-19 and concluded that the risk of developing a serious heart rhythm problem is more than five times greater. As a result, the WHO suspended the trials using the drug and France banned it.
There is a recent peer reviewed paper that disputes your position.
originally posted by: carewemust
For every study saying Hydroxychloroquine is Not-Effective against Covid-19, there is a study saying that it is Effective.
Since HCQ not a dangerous medication, can't hurt to give it a try. "Right to Try".
I gave it read the thread
Check out my threads it’s in the top three it has 50 flags
The study was published today in the International Journal of Infectious Diseases, the peer-reviewed, open-access online publication of the International Society of Infectious Diseases (ISID.org).
Brazilian chloroquine study halted after high dose proved lethal for some patients
The
preliminary
findings from CloroC
ovid
-
19 trial suggest th
at
the
higher dosage of CQ
(
12 g
total dose over
10 days
)
in COVID
-
19
should
no
t
be
recommended because
of
safety
concerns regarding
QTc prolongation and
increased lethality
,
in the Brazilian population
, and
more often in older patients in use of drugs such as azithromycin and oseltamivir, which also
prolong QTc interval
.
Among patients randomized to the lower dosage group (5 days of
tr
eatment
, total dose 2.7 g
)
,
given the limited number of patients so far enrolled, it is still not
possible to estimate a clear benefit of CQ in
patients
with
severe ARDS. Preliminary data on
viral clearance
in respiratory
secretions
in our
confirmed cases
are also indicative of little
effect of the drug at high dosage
.
More studies
initiating
CQ
prior to the onset of the
severe
phase of the disease are urgently needed
Th
e protocol
was
timely
approved by the
Brazilian Committee of Ethics
in Human Research
(
CONEP
a
pproval 3.929.646
/2020). All patients and/or legal representatives in case of
unconsciousness, were
informed
about objectives and risks of participation
. They
were given
time to
carefully
read and then sign an informed consent form (ICF). After recovery, the
patient also signed the ICF. Random online clinical monitoring and quality control was
performed. A virtu
al
independent
Data Safety and Monitoring Board
(DSMB), with
epidemiologists, clinicians and experts in
i
nfectious
d
iseases, was timely implemented to
review the protocol
and with
daily meetings to
follow
-
up
the activities of the study
. The trial
was
reported according to
Consolidated Standards of Reporting Trials
(Consort) statement
.
32
Study
design and
site
CloroC
ovid
-
19
was
a parallel, double
-
blind, randomized, phase IIb clinical trial
,
which
started
on March
2
3
rd
,
2020
,
aiming
to assess
safety
and efficacy
of
CQ
in the
treatment of
hospitalized patients with severe respiratory syndrome secondary to SARS
Participants
Hospitalized patients aged 18 years or older at the time of inclusion, with respiratory
rate
higher than 24 rpm AND/OR
heart rate higher than 125 bpm (in the absence of fever)
AND/OR peripheral oxygen saturation lower than 90% in ambient air AND/OR shock